CRI Acquires Lifetree Creating a Specialized Research Organization
CRI Worldwide
, LLC (CRI) announced that it has completed the acquisition of
Lifetree Clinical Research®, LC (Lifetree)
.
The combination enables them to tap into CRI’s experience in Psychiatry and patient population studies as well as Lifetree’s experience in Pain Management and Human Abuse Liability and in performing complex studies.
The acquisition expands CRI’s Clinical Pharmacology capacity to more than 120 beds. The combined organization will provide sponsors with access to more than 6 million people along with a broad range of psychiatry and neurology research products and services at three research sites located in New Jersey, Pennsylvania, and Utah.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025